Alembic Pharmaceuticals Ltd Q1 FY2024 Concall Summary

Key Takeaways

• Solid headline growth, new-plant costs absorbed: Revenue rose 18% to ₹1,486 crore and EBITDA grew 67% (adjusted), all while the P&L carried the full cost of three newly capitalized plants for the first time.
• India branded business slowed late in the quarter: The 9% growth to ₹524 crore was dampened by a delayed monsoon that softened acute sales, a pattern management expects to reverse as the season extends into Q3.
• US generics still a price-erosion story: Revenue grew 6% in rupee terms, but double-digit price erosion persists molecule by molecule; the strategy leans on supply-chain reliability and capturing shortage-driven opportunities.
• R&D spend is the margin lever for FY24: The plan to cut R&D from ~₹600 crore to ~₹500 crore, plus fixed overhead absorption on sales growth, is the stated path to margin expansion.
• What to watch next quarter: Whether the monsoon-driven domestic pickup materializes, the pace of injectable product launches from the new facilities, and any signal on US price erosion easing further.

India Branded Business

• Growth above market, then a soft patch: External sales grew 11% vs. the industry's 9%, led by specialty therapy (12%), acute (16%), and anti-infective (19%). The back end of the quarter softened as an extended summer and delayed monsoon slowed acute offtake.
• Seasonality pattern is now familiar: Management noted that for the last three years, a delayed monsoon has pushed the acute season later, making Q3 significantly better than Q2. No margin pressure is seen in the domestic business, and no manpower expansion is planned this year.
• Animal health gets a dedicated push: The company added ~200 people and created a separate vertical for feed products in the large-cattle space, with launches lined up in non-antibiotic feed, probiotics, and mainline veterinary products. Management is "very bullish" and growing organically.

Shaunak Amin: "It is just a matter of a delayed onset with kind of slows things down... usually we have seen that delayed onset usually leads for long season on the back end, so usually for the last 3 years, we have seen the Q3 has been significantly better in terms of seasonality compared to Q2."

US Generics: Pricing, Shortages & New Capacity

• Price erosion still double-digit, but possibly moderating: Management confirmed erosion continues, though it may be less severe than six months ago. Regulatory actions against some facilities have reduced supply on certain products, creating shortage opportunities that Alembic's compliance-focused strategy aims to capture.
• The shortage playbook is unchanged: The company has historically performed well during supply disruptions, and management sees that fundamental intact. Shortages persist per the FDA shortage report, though "there is still quite a bit of supply in the market."
• New facilities are live and launching: The F4 oral solid dosage facility received its EIR after a December FDA inspection and has two product approvals. From the two injectable facilities (onco and general), five products are now commercialized. The final pending line at the F3 injectable plant was capitalized in Q1.
• Injectable ramp is early and unguided: With only five products launched, the portfolio is nascent. Management declined to give revenue guidance or an asset-turnover plan, citing extreme product-level price variability in the current US environment.

Pranav Amin: "For the last 6-7 years that we have been in the US market, we have always done well when there are shortages in the market and we have been able to capture those opportunities. So that fundamental still stays because inherently our strategy is focused on a very robust supply chain and having compliance at our facilities."

API & Ex-US Generics

• API growth guided at 10–15%: The API business grew 31% this quarter and management stood by its full-year growth guidance of 10–15%, citing a strategy built on supply-chain robustness and compliance.
• Margin dynamics are a pass-through: Raw material price declines are passed on to finished-product prices as competition enters, so margins are maintained rather than expanded. The company was not significantly hurt when raw material prices rose, as it was covered.
• Ex-US formulations grew 46%: Management expressed confidence that both the ex-US formulation and API businesses will perform in coming quarters.
• Capacity expansion continues: The company will keep adding blocks and facilities within existing plants to support API growth.

Costs, Margins & the P&L Reset

• New-plant costs are now fully in the P&L: From January 1, no further costs were capitalized; from April 1, depreciation on the three new plants (F2, F3, F4) began hitting the P&L. As plants gain approvals and launch products, manpower and utility costs are being revamped, making quarter-on-quarter cost comparisons difficult.
• Gross margin steady; overheads are the drag: Gross margin has been maintained and raw material costs have been fairly steady. The margin compression has come from increased overheads, not from gross margin deterioration.
• The margin expansion thesis: Management expects fixed overheads to stay at current levels, so sales growth should drive operating leverage. The R&D spend reduction from ~₹600 crore to ~₹500 crore this year is an additional tailwind.
• Aleor integration is done: Aleor is now a division, not a subsidiary. The ~₹1,100 crore impairment of pre-operative expenses was taken last year and spread over two years for tax benefit; no further write-offs are expected.

R. K. Baheti: "aspirational margin without really linking it with our current performance would be back to 18%-20%."

Capital Allocation & Balance Sheet

• Capex is winding down: Total capex for the year, including Q1, is guided at ₹300–350 crore, and likely lower going forward. Major projects are complete; the only new build is a domestic formulation facility at Pithampur, Indore. Future capex will be largely maintenance.
• Debt repayment first, then opportunities: Borrowings of ~₹550–600 crore will be repaid from operating cash flow. After that, the company will look for further deployment opportunities.
• Tax rate path: FY24 tax rate is expected to be lower because the Aleor impairment is claimed as a deductible expense. FY25 should revert to the MAT rate of 17–18%. Management declined to give a ballpark FY24 figure, as it depends on total profit minus the impairment.

Guidance & Commitments

Key Metrics